keyword
MENU ▼
Read by QxMD icon Read
search

advanced colorectal cancer

keyword
https://www.readbyqxmd.com/read/28743105/statistical-interactions-from-a-growth-curve-perspective
#1
Sean M Devlin, Jaya M Satagopan
Logistic regression is widely used to evaluate the association between risk factors and a binary outcome. The logistic curve is symmetric around its point of inflection. Alternative families of curves, such as the additive Gompertz or Guerrero-Johnson models, have been proposed in various scenarios due to their asymmetry: disease risk may initially increase rapidly and be followed by a longer period where the rate of growth slowly decreases. When modeling binary outcomes in relation to risk factors, an additive logistic model may not provide a good fit to the data...
July 26, 2017: Human Heredity
https://www.readbyqxmd.com/read/28742796/leukocyte-telomere-length-and-renal-cell-carcinoma-survival-in-two-studies
#2
Catherine L Callahan, Kendra Schwartz, Julie J Ruterbusch, Brian Shuch, Barry I Graubard, Qing Lan, Richard Cawthon, Andrea A Baccarelli, Wong-Ho Chow, Nathaniel Rothman, Jonathan N Hofmann, Mark P Purdue
BACKGROUND: Leukocyte telomere length (LTL) is a potential biomarker of cancer prognosis; however, evidence for renal cell carcinoma (RCC) is inconsistent. METHODS: We investigated LTL and RCC-specific survival among 684 cases from the US kidney cancer study (USKC) and 241 cases from the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO). Leukocyte telomere length was measured by quantitative polymerase chain reaction, and hazard ratios (HRs) and 95% confidence intervals (CIs) computed using multivariable Cox models...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28742793/intracrine-vegf-signalling-mediates-colorectal-cancer-cell-migration-and-invasion
#3
Rajat Bhattacharya, Fan Fan, Rui Wang, Xiangcang Ye, Ling Xia, Delphine Boulbes, Lee M Ellis
BACKGROUND: Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are key regulators of angiogenesis, affecting endothelial cell survival and function. However, the effect of VEGF-VEGFR signalling on tumour cell function is not well understood. Our previous studies in colorectal cancer (CRC) cells have demonstrated an intracrine VEGF/VEGFR1 signalling mechanism that mediates CRC cell survival and chemo-sensitivity. Since extracellular VEGF signalling regulates migration of endothelial cells and various tumour cells, we attempted to determine whether intracrine VEGF signalling affects CRC cell motility...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28742792/evidence-for-genetic-association-between-chromosome-1q-loci-and-predisposition-to-colorectal-neoplasia
#4
Stephanie A Schubert, Dina Ruano, Fadwa A Elsayed, Arnoud Boot, Stijn Crobach, Arantza Farina Sarasqueta, Bruce Wolffenbuttel, Melanie M van der Klauw, Jan Oosting, Carli M Tops, Ronald van Eijk, Hans Fa Vasen, Rolf Ham Vossen, Maartje Nielsen, Sergi Castellví-Bel, Clara Ruiz-Ponte, Ian Tomlinson, Malcolm G Dunlop, Pavel Vodicka, Juul T Wijnen, Frederik J Hes, Hans Morreau, Noel Fcc de Miranda, Rolf H Sijmons, Tom van Wezel
BACKGROUND: A substantial fraction of familial colorectal cancer (CRC) and polyposis heritability remains unexplained. This study aimed to identify predisposing loci in patients with these disorders. METHODS: Homozygosity mapping was performed using 222 563 SNPs in 302 index patients with various colorectal neoplasms and 3367 controls. Linkage analysis, exome and whole-genome sequencing were performed in a family affected by microsatellite stable CRCs. Candidate variants were genotyped in 10 554 cases and 21 480 controls...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28742190/the-research-on-the-influences-of-hyperthermal-perfusion-chemotherapy-combined-with-immunologic-therapy-on-the-immunologic-function-and-levels-of-circulating-tumor-cells-of-the-advanced-colorectal-cancer-patients-with-liver-metastasis
#5
J-J Sun, G-L Fan, X-G Wang, K Xu
OBJECTIVE: To investigated the influence of hyperthermal perfusion chemotherapy combined with immunologic therapy on the immunologic function and levels of circulating tumor cells of the advanced colorectal cancer patients with liver metastasis. PATIENTS AND METHODS: We enrolled 98 advanced colorectal cancer patients with liver metastasis that were admitted to this hospital for treatment and were randomly divided into two groups, the observation group (n = 49) and the control group (n = 49)...
July 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28741478/targeting-the-microenvironment-in-advanced-colorectal-cancer
#6
REVIEW
Daniele V F Tauriello, Eduard Batlle
Colorectal cancer (CRC) diagnosis often occurs at late stages when tumor cells have already disseminated. Current therapies are poorly effective for metastatic disease, the main cause of death in CRC. Despite mounting evidence implicating the tumor microenvironment in CRC progression and metastasis, clinical practice remains predominantly focused on targeting the epithelial compartment. Because CRCs remain largely refractory to current therapies, we must devise alternative strategies. Transforming growth factor (TGF)-β has emerged as a key architect of the microenvironment in poor-prognosis cancers...
September 2016: Trends in Cancer
https://www.readbyqxmd.com/read/28736848/the-risk-of-colorectal-neoplasia-can-be-different-according-to-the-types-of-family-members-affected-by-colorectal-cancer
#7
Nam Hee Kim, Hyo-Joon Yang, Soo-Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn, Yoon Suk Jung
BACKGROUND: A family history of colorectal cancer (CRC) is an important risk factor for CRC, but more detailed data are needed to prepare effective screening guidelines. We aimed to evaluate the risk of colorectal neoplasia (CRN) among individuals with different relatives affected by CRC (the first-degree relatives [FDRs] or the second-degree relatives [SDRs] or the first cousins) and to assess the effects of family histories according to age groups (30-39, 40-49, and ≥50 years). METHODS: A cross-sectional study was performed on 98,562 asymptomatic examinees aged ≥ 30 years who underwent colonoscopy as part of a health check-up...
July 24, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28736761/phase-ii-study-of-dovitinib-in-patients-progressing-on-anti-vascular-endothelial-growth-factor-therapy
#8
Thomas J Semrad, Edward J Kim, Michael S Tanaka, Jacob Sands, Chris Roberts, Rebekah A Burich, Yu Li, David R Gandara, Primo Lara, Philip C Mack
BACKGROUND: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment. METHODS: Patients with measurable advanced colorectal or non-small cell lung cancer with progression despite anti-VEGF treatment within 56 days, good performance status and adequate organ function were eligible...
2017: Cancer Treat Res Commun
https://www.readbyqxmd.com/read/28736637/primary-and-acquired-resistance-to-biologic-therapies-in-gastrointestinal-cancers
#9
REVIEW
Sam J Lubner, Nataliya V Uboha, Dustin A Deming
Improvements in the understanding of cancer biology have led to therapeutic advances in the treatment of gastrointestinal cancers. Drugs which target the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways have led the way in colon cancer. Monoclonal antibodies (mAbs) such as bevacizumab, ramucirumab, cetuximab, and panitumumab, have improved progression free survival and overall survival (OS) for colorectal cancers and were quickly adopted. Human epidermal growth factor receptor 2 (HER2) has demonstrated significant benefit for gastroesophageal cancers and in the setting of HER2 amplification, trastuzumab in combination with chemotherapy has become the standard of care...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28736632/biologics-in-bowel-cancer
#10
REVIEW
Marcus S Noel
Colorectal cancer is the third most common cancer in the United States and second leading cause of cancer death with over 50,000 patients expected to die from their disease in 2017. For patients who present at diagnosis with advanced disease the standard treatment is systemic chemotherapy. Over the last decade a number of biologic therapies have emerged as viable treatment options for advance colorectal cancer. When these new drugs are combined with chemotherapy survival is prolonged, often without a detriment to quality of life...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28736627/personalized-and-precision-medicine-integrating-genomics-into-treatment-decisions-in-gastrointestinal-malignancies
#11
REVIEW
Trang H Au, Kai Wang, David Stenehjem, Ignacio Garrido-Laguna
The advent of next generation sequencing (NGS) technologies has advanced our understanding of the intrinsic biology of different gastrointestinal (GI) tumor types. The use of novel, more efficient sequencing platforms has improved turnaround times of sequencing results. This is providing real time opportunities to put precision medicine to the test. A number of early phase clinical trials are testing targeted therapies in unique molecularly characterized subsets of patients (baskets). While basket studies are gaining momentum, treatment failures serve to remind us that shifting from a histology-driven to a histology-agnostic approach is unlikely to be a failure-free strategy for a number of tumor types as recently learnt from vemurafenib failure in BRAF mutated metastatic colorectal cancer (mCRC)...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28733868/impact-of-age-on-the-risk-of-advanced-colorectal-neoplasia-in-a-young-population-an-analysis-using-the-predicted-probability-model
#12
Yoon Suk Jung, Chan Hyuk Park, Nam Hee Kim, Mi Yeon Lee, Dong Il Park
BACKGROUND: The incidence of colorectal cancer is decreasing in adults aged ≥50 years and increasing in those aged <50 years. AIMS: We aimed to establish risk stratification model for advanced colorectal neoplasia (ACRN) in persons aged <50 years. METHODS: We reviewed the records of participants who had undergone a colonoscopy as part of a health examination at two large medical examination centers in Korea. By using logistic regression analysis, we developed predicted probability models for ACRN in a population aged 30-49 years...
July 21, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28733646/prognostic-role-of-glasgow-prognostic-score-in-patients-with-colorectal-cancer-evidence-from-population-studies
#13
Yangyang Liu, Xingkang He, Jie Pan, Shujie Chen, Liangjing Wang
Glasgow prognostic score (GPS) has been reported to be an indicator of prognosis for various cancers. However, the relationship between GPS and colorectal cancers (CRC) remains unclear. A comprehensive search of Pubmed, Embase, Cochrane library, Web of Science, ChinaInfo and Chinese National Knowledge Infrastructure was performed to identify eligible studies, from which the risk of overall survival (OS) and cancer-specific survival (CSS) were extracted. A random-effect model was adopted to combine hazard ratio (HR) and 95% confidence interval (CI)...
July 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28733262/cost-effectiveness-of-high-performance-biomarker-tests-vs-fecal-immunochemical-test-for-non-invasive-colorectal-cancer-screening
#14
Iris Lansdorp-Vogelaar, S Lucas Goede, Linda J W Bosch, Veerle Melotte, Beatriz Carvalho, Manon van Engeland, Gerrit A Meijer, Harry J de Koning, Marjolein van Ballegooijen
BACKGROUND: Biomarker assays could increase the accuracy of non-invasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening. We investigated the conditions under which biomarker screens would be cost-effective compared to FIT screens of average risk individuals. METHODS: We used the MISCAN-colon microsimulation model to estimate the effects of various CRC screening test characteristics on life years gained (LYG) and costsBiomarker assays could increase the accuracy of non-invasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening...
July 18, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28732671/psoas-hitch-ureteral-reimplantation-after-surgery-for-locally-advanced-and-locally-recurrent-colorectal-cancer-complications-and-oncological-outcome
#15
F van den Heijkant, T A Vermeer, E J E J Vrijhof, G A P Nieuwenhuijzen, E L Koldewijn, H J T Rutten
INTRODUCTION: The most important prognostic factor for oncological outcome of rectal cancer is radical surgical resection. In patients with locally advanced T4 rectal cancer (LARC) or locally recurrent rectal cancer (LRRC) (partial) resection of the urinary tract is frequently required to achieve radical resection. The psoas bladder hitch (PBH) technique is the first choice for reconstruction of the ureter after partial resection and this bladder-preserving technique should not influence the oncological outcome...
May 26, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28731192/anp32a-modulates-cell-growth-by-regulating-p38-and-akt-activity-in-colorectal-cancer
#16
Wei Yan, Zhun Bai, Juan Wang, Xumei Li, Bixia Chi, Xu Chen
Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) possesses multiple biochemical activities, has been found to be decreased or absent in malignant tumors. However, new findings have shown that it is expressed in greater amounts in advanced cancers than in early-stage tumors. The role and clinical significance of ANP32A in colorectal cancer (CRC) is still unknown. In the present study, the expression of ANP32A was assessed in 68 CRC patients by IHC, and then the correlation of its expression with clinicopathological factors was investigated using the Allred, Klein and immune response scoring system analysis...
July 21, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28731151/meg3-is-a-prognostic-factor-for-crc-and-promotes-chemosensitivity-by-enhancing-oxaliplatin-induced-cell-apoptosis
#17
Lixia Li, Jian Shang, Yupeng Zhang, Shi Liu, Yanan Peng, Zhou Zhou, Huaqing Pan, Xiaobing Wang, Lipng Chen, Qiu Zhao
A major reason for the failure of advanced colorectal cancer (CRC) treatment is the occurrence of chemoresistance to oxaliplatin-based chemotherapy. Recently, studies have shown that long non-coding RNAs (lncRNAs) play an important role in drug resistance. Using HiSeq sequencing methods, we identified that lncRNAs show differential expression levels in oxaliplatin-resistant (OxR) and non-resistant CRC patients. RT-qPCR was then performed in tissues and serum samples, and lncRNA MEG3 was verified to be downregulated in non-responding patients and to have considerable discriminating potential to identify responding patients from non-responding patients...
July 17, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28731136/mhy451-induces-cell-cycle-arrest-and-apoptosis-by-ros-generation-in-hct116-human-colorectal-cancer-cells
#18
Na Lam Hwang, Yong Jung Kang, Bokyung Sung, Seong Yeon Hwang, Jung Yoon Jang, Hye Jin Oh, Yu Ra Ahn, Do Hyun Kim, Su Jeong Kim, Sultan Ullah, Mohammad Akbar Hossain, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim
Colorectal cancer (CRC) is the third most frequently diagnosed cancer and cause of cancer-related deaths. Despite advancements in conventional therapeutic approaches to CRC, most patients with CRC die of their disease. There is a need to develop novel therapeutic agents for this malignancy. Therefore, the present study aimed to examine the anticancer effects and elucidate the underlying mechanism of MHY451 in HCT116 human colorectal cancer cells. Treatment with MHY451 inhibited cell growth in a time- and concentration-dependent manner...
July 18, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28730759/surgical-treatment-for-colorectal-cancer-in-octogenarians-and-nonagenarians
#19
Young Wan Kim
Advances in surgical techniques and perioperative care have improved cancer-related outcomes. However, there are still concerns regarding the safety of octogenarian and nonagenarian patients during surgery. Clinicians may be reluctant to perform a radical resection for colorectal cancer and administer adjuvant or palliative cytotoxic chemotherapy to octogenarian and nonagenarian patients. In the elderly, setting a primary goal based on multidisciplinary team discussions prior to treatment is important. The overall treatment scheme, risks, and potential benefits should be discussed with elderly patients and their families...
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28728314/local-recurrence-and-its-risk-factor-after-incomplete-resection-of-colorectal-advanced-adenomas-a-single-center-retrospective-study
#20
Dae Myung Oh, Jae Kwang Lee, Hyunsoo Kim, Chang Keun Park, Jae Kwon Jung, Dae Jin Kim, Yun Jin Chung, Tae Hoon Kim, Myung Il Park, Jong Pil Park
Background/Aims: Colonoscopy can detect precancerous lesions, which can subsequently be removed and reduce incidences of and mortality from colorectal cancer (CRC). However, recently published data have highlighted a significant rate of CRC in patients who previously underwent colonoscopy. Among many reasons, incomplete resection has been considered as a significant contributor. However, to date, there have only been a few studies regarding incompletely resected polyps, especially advanced colorectal adenoma (ACA)...
July 25, 2017: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
keyword
keyword
32505
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"